Menu
← Oncology Approval Tracker
FDA DECISION ·
Omisirge
omidubicel-onlv · Gamida Cell
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
To reduce time to neutrophil recovery and lower infection incidence in patients aged 12 or older with hematologic malignancies who are scheduled for cord blood transplant after myeloablative conditioning.
LAMPGEN ANALYSIS
Why it matters
The approval targeted engraftment and infection risk in patients undergoing cord blood transplantation.
What research teams should watch
Coordinate product availability, conditioning and transplant timing, with prespecified recovery and infection assessments.
PRIMARY RECORDS